eXmoor Pharma and Anthony Nolan: Cell Therapy & Laboratory Services (CT&LS) have announced a strategic partnership to provide integrated support for developers of autologous and allogeneic cell therapies. The collaboration combines donor material expertise with GMP manufacturing capabilities.
The partnership offers a complete service spanning donor sourcing, screening, apheresis collection, process development and clinical-grade manufacturing. It aims to simplify the path from starting material to clinical supply while prioritising patient and donor welfare.
Anthony Nolan’s CT&LS will supply starting material through its donor register of over 900,000 HLA-typed individuals, bioinformatics tools, cord blood programme and a new apheresis centre in Nottingham. The organisation brings over 50 years of donor care experience.
eXmoor will process the material at its GMP facility in Bristol, offering fill-finish, process development and manufacturing services. The company has passed Anthony Nolan CT&LS’s ethical review board, ensuring aligned standards across the collaboration.
Lucy Foley, CEO of eXmoor Pharma, said: “We are proud to partner with Anthony Nolan’s CT&LS, powered by a UK institution with unmatched expertise in donor services and ethical sourcing. Together, we can offer cell therapy developers a truly integrated path from donor to patient.”
David Bennett, Director of Business Development for Anthony Nolan’s Cell Therapy and Lab Services, said: “Our 50+ years of experience in working with donors and our large and diverse register, make Anthony Nolan’s CT&LS the obvious choice for partners like eXmoor who are looking to accelerate therapy development.”
The partnership is designed to reduce complexity, shorten timelines and uphold the highest ethical and clinical standards in cell therapy development.
